AMZN
Amazon.com, Inc.
AMZN has the edge over BLBD overall, supported by stronger modeled upside and lower modeled downside.
BLBD
Blue Bird Corporation
BLBD offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
BLBD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
BLBD's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
BLBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6.8x | $55.45 | — |
| Cheap | 13x | $103 | +85% |
| Forward | 13x | $55.45 | — |
| Fair | 17x | $138 | +150% |
| Expensive | 39x | $320 | +476% |
Historical ranges are pointers, not guarantees.
BLBD has the edge over AMZN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over BLBD on the outlook, with more favorable earnings and profitability expectations.
BLBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect BLBD's revenue to grow, but its profitability to weaken.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over BLBD on earnings, with stronger typical year-over-year growth.
BLBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | -46% |
| Q2 2026 | $8.22 | +136% |
| Q1 2026 | $4.07 | +27% |
| Q4 2025 | $3.96 | +23% |
| Q3 2025 | $3.88 | +23% |
| Q2 2025 | $3.48 | +15% |
| Q1 2025 | $3.21 | +30% |
| Q4 2024 | $3.21 | +69% |
| Q3 2024 | $3.16 | +327% |
BLBD's earnings per share have climbed steadily: $8.22 over the past year, up 136% from the year before, and higher year over year for 13 quarters in a row. Its recent earnings include one-off gains.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over BLBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over BLBD on profitability, with a higher operating margin.
BLBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $517.2M | +30% |
| Q1 2026 | $352.6M | -1.7% |
| Q4 2025 | $333.1M | +6.1% |
| Q3 2025 | $409.4M | +17% |
| Q2 2025 | $398M | +19% |
| Q1 2025 | $358.9M | +3.7% |
| Q4 2024 | $313.9M | -1.2% |
| Q3 2024 | $350.2M | +16% |
BLBD's revenue is growing: $517M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -0.5 points |
| Q1 2026 | 11% | +1.7 points |
| Q4 2025 | 11% | +0.8 points |
| Q3 2025 | 12% | +5 points |
| Q2 2025 | 13% | +0.7 points |
| Q1 2025 | 9.4% | -1 points |
| Q4 2024 | 11% | -1.4 points |
| Q3 2024 | 7.3% | -2.3 points |
BLBD's operating margin was 12% last quarter, about level with the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
BLBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $21.7M | -59% |
| Q1 2026 | $39.9M | +113% |
| Q4 2025 | $31.1M | +43% |
| Q3 2025 | $60.5M | +20% |
| Q2 2025 | $52.3M | +$55.8M |
| Q1 2025 | $18.7M | -64% |
| Q4 2024 | $21.8M | +$24.5M |
| Q3 2024 | $50.2M | +49% |
BLBD has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over BLBD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
BLBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.4% | +2.7M shares |
| 1 year | +7.9% | +2.6M shares |
| 3 years | +7.8% | +2.6M shares |
| 5 years | +28% | +7.7M shares |
| Available history | +30% | +8.1M shares |
BLBD has 35M diluted shares, up 7.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $198,000 |
| Q4 2025 | $2.4M |
| Q3 2025 | $5.5M |
| Q2 2025 | — |
| Q1 2025 | $3M |
| Q4 2024 | $1.4M |
| Q3 2024 | $877,000 |
BLBD spent $8M buying back its own shares over the past year, up 52% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
BLBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.8x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
| Q3 2024 | -0.2x | Net Cash |
BLBD has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
BLBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 8.2 | Oversold |
BLBD's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
BLBD PE vs Consumer Cyclical Sector
| Metric | BLBD | Sector median | Relative |
|---|---|---|---|
| PE | 6.8x | 18x | 63% below |
| PE % | 0 | 47 | 47 pts below |
BLBD has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over BLBD on trend strength, trading above more of its moving averages.
BLBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $56.9 | 2.6% below |
| 20 week MA | $63.9 | 13% below |
| 50 week MA | $61.2 | 9.4% below |
| 100 week MA | $52.7 | 5.1% above |
| 200 week MA | $42.1 | 32% above |
BLBD has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 32% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over BLBD on returns for 2026, with the stronger performance.
BLBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.0 | $19.1 | -17% |
| 2021 | $19.1 | $14.7 | -23% |
| 2022 | $14.7 | $9.97 | -32% |
| 2023 | $9.97 | $27.0 | +170% |
| 2024 | $27.0 | $39.4 | +46% |
| 2025 | $39.4 | $50.7 | +29% |
| 2026 YTD | $50.7 | $55.5 | +9.3% |
BLBD has finished lower in three of the last six years. It's up 9.3% so far in 2026.